June 2021 - Page 2 of 5 - PsychedelicNewsWire (PNW)

TuesdayJun 22, 2021 9:45 am

Could Psychedelics Be Used to Understand Near-Death Experiences?

For decades now, researchers have been unable to decipher what exactly causes a near-death experience. While most scientific studies haven’t delved into the study of near-death experiences, researchers have discovered that the characteristics of these incidents remain constant 20 years after they occurred. This discovery offers researchers an opportunity to learn more about these incidents first-hand and call attention to the foundational characteristics of near-death experiences. A recent study found that near-death experiences were marked by the infamous tunnel of light, an out-of-body experience and a feeling of inner peace. Additionally, scientists are discovering that psychedelics may play a big…

MondayJun 21, 2021 1:15 pm

Researchers ID Psychedelic Analog That Counters Effects of Stress in Mice

New research conducted by researchers from the University of California-Santa Cruz has found that an individual dose of tabernanthalog (“TBG”) can repair neural circuits in the brain that are damaged by stress, enhance neuronal connection regrowth and remedy behavioral deficits such as cognitive inflexibility and anxiety that are caused by stress. TBG is a new compound that has a structure similar to ibogaine, a psychedelic drug. Prior studies have found that while ibogaine has the potential to treat addiction, it is also a powerful hallucinogen and can cause severe heart arrhythmias. However, unlike ibogaine, TBG lacks hallucinogenic and toxic effects.…

FridayJun 18, 2021 2:45 pm

Mike Tyson Asserts That Psilocybin Helped Change His Life

Towards the end of last year, Mike Tyson took on Ray Jones Jr. in a boxing match for the first time in more than a decade. In a pay-per-view exhibition, the two boxed, ending the eight-round fight 78 to 74 for Tyson. During an interview with Reuters, Mike Tyson, commonly known as Iron Mike, revealed that he had struggled with drug addiction in his life, asserting that the use of psilocybin helped him get back on his feet. He explained that once he was introduced to psilocybin mushrooms, his whole life changed, adding that the shrooms had helped him when…

ThursdayJun 17, 2021 2:45 pm

Scientists Study Psychopathology Through Social Dominance Lens

A report published recently in PLOS One revealed that the symptoms of mental health conditions affected how individuals responded to being placed in subordinate and dominant positions. The research stated that depressive and manic symptoms especially were linked to physiological and psychological responses to social dominance. CALM Program director Sheri Johnson, who is also a University of California psychology professor and the author of the study, stated that she had collaborated with her associates to review the literature on psychopathology and social dominance. Johnson explained that there were various studies suggesting how important social dominance was to various forms of…

ThursdayJun 17, 2021 10:54 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces First-Ever Trial to Treat COVID-19 Frontline Clinicians, Unveils EMBARK Model

The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stress EMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine Cybin considers it an honor, duty to support healing processes of doctors, nurses and healthcare professionals, says CEO In the first-ever study of its kind, Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it is co-sponsoring a study focused on treating frontline clinicians experiencing COVID-related distress (https://ibn.fm/NvMAo). In addition to co-sponsoring the study, Cybin also announced the development of EMBARK, a groundbreaking…

WednesdayJun 16, 2021 10:39 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference

Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needs The company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare Conference Tryp’s synthetic psychedelic drug candidate will be further developed in an upcoming phase 2a clinical study in partnership with pediatric eating disorders expert Jennifer Miller, M.D. at the University of Florida The trial will focus on Tryp’s flagship candidate, TRP-8802, in treating binge eating and hypothalamic obesity The company expects to begin manufacturing its…

WednesdayJun 16, 2021 9:30 am

Coronavirus Pandemic Prompts Increases in Eating Disorders Among Adults, Teenagers

Eating disorders affect about 9% of individuals across the globe. Data from the National Association of Anorexia Nervosa and Associated Disorders shows that eating disorders cause nearly 10,000 deaths in the United States annually and impact roughly 30 million individuals. Physicians and other specialists have observed an increase in the numbers of patients seeking help for eating disorders, noting that the pandemic has prompted an increase in the number of eating disorders as well as relapses. Jennifer Wildes, the director of the University of Chicago’s outpatient eating disorders program, stated that the program had recorded significant increases. Wildes, who is…

TuesdayJun 15, 2021 2:45 pm

Why NIH Should Get Involved in Psychedelics Research

Investing in medicinal psychedelic research in the recent past was considered risky. Now, however, financiers and entrepreneurs are injecting money into the development of psychedelic therapies for behavioral and mental health issues. Despite this, one of the biggest public financiers of medical research in the world — the National Institutes of Health — is yet to do so. The organization’s absence in psychedelic medicine may potentially be slowing the development of new innovative treatments as well as preventing researchers from entering the field. Records show that various human populations have used psychedelics such as psilocybin, mescaline, MDMA, LSD, ibogaine, DMT…

TuesdayJun 15, 2021 1:17 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commences Sale of Rapid COVID-19 RT-PCR Test Kits in Germany Amid Potential Surge in Demand

XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25 Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the market The announcement comes as Germany reopens, meaning XPhyto is likely to benefit from a raft of regulatory requirements instituted by the government, which could potentially increase demand The Covid-ID Labs is both fast and accurate, factors that could make it the go-to product, given the inaccuracies and low sensitivity of many rapid antigen tests As…

TuesdayJun 15, 2021 9:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Expands Sales into Public Sector with BC Liquor Distribution Board Purchase

PULL secures edible cannabis gummies order from British Columbia Liquor Distribution Branch PULL’s cannabis gummies produced in blister packs using proprietary manufacturing system licensed from US-based Taste-T, LLC SKUs include 10 mg THC options in Fire Burst, Strawberry, and Mango flavors, three additional non-THC SKUs currently in development Global CBD gummies market estimated at $1.6 billion in 2020, 30.7% CAGR from 2021 to 2028 Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, recently secured an initial purchase order through subsidiary Pure Extracts Manufacturing Corp., from…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: June 2021